Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Glucagon

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    MetaVia Doses First Patient in Higher-Dose Ph 1 Study of DA-1726
    MetaVia Doses First Patient in Higher-Dose Ph 1 Study of DA-1726

    10 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/metavia-doses-the-first-patient-in-higher-dose-phase-1-study-of-da-1726-its-glp-1-and-glucagon-dual-agonist-for-the-treatment-of-obesity-302738622.html

    PR NEWSWIRE
    10 Apr 2026
    Share Share
    Government Enhances Oversight On Unauthorized GLP-1 Sales
    Government Enhances Oversight On Unauthorized GLP-1 Sales

    24 Mar 2026

    // BUSINESS STD

    https://www.business-standard.com/industry/news/centre-tightens-checks-on-generic-weight-loss-drugs-126032400478_1.html

    BUSINESS STD
    24 Mar 2026
    Share Share
    Lilly's Retatrutide Shows Promising Results In Type 2 Diabetes
    Lilly's Retatrutide Shows Promising Results In Type 2 Diabetes

    19 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-demonstrated-significant-reductions-in-a1c-and-weight-in-first-phase-3-trial-for-treatment-of-type-2-diabetes-302718589.html

    PR NEWSWIRE
    19 Mar 2026
    Share Share
    Metavia To Unveil DA-1726 Phase 1 Data At Obesityweek 2025
    Metavia To Unveil DA-1726 Phase 1 Data At Obesityweek 2025

    05 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/metavia-to-present-new-phase-1-and-pre-clinical-data-on-da-1726-at-obesityweek-2025-302604527.html

    PR NEWSWIRE
    05 Nov 2025
    Share Share
    Cipla`s Generics Glucagon Receives Approval in US
    Cipla`s Generics Glucagon Receives Approval in US

    15 Sep 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218813

    FDA
    15 Sep 2025
    Share Share
    American Regent® Launches Gvoke VialDx™ (glucagon injection)
    American Regent® Launches Gvoke VialDx™ (glucagon injection)

    27 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/american-regent-launches-gvoke-vialdx-glucagon-injection-302539306.html

    PR NEWSWIRE
    27 Aug 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.